| Literature DB >> 34967689 |
Anca Pantea Stoian1,2, Peter Kempler3, Thomas Stulnig4, Ali A Rizvi5,6, Manfredi Rizzo1,6,7.
Abstract
As the world enters its third year of the COVID-19 pandemic, individuals with diabetes have faced particular challenges from the virus. A deleterious bidirectional relationship exists between the two disorders, with heightened inflammatory, immunologic, and cellular mechanisms leading to a more severe illness and increased morbidity and mortality. Tight glucose control, though necessary, is hampered by physical restrictions and difficulty accessing health care. Novel glucose-lowering medications may provide unique benefits in this regard. It is imperative that multi-pronged efforts be prioritized in order to reduce adverse outcomes in patients with diabetes at risk for COVID-19.Entities:
Keywords: COVID-19; cardiometabolic risk; complications; diabetes; obesity; treatment
Mesh:
Substances:
Year: 2021 PMID: 34967689 DOI: 10.1089/met.2021.0133
Source DB: PubMed Journal: Metab Syndr Relat Disord ISSN: 1540-4196 Impact factor: 1.894